You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Aspirin-PC for Chemoprevention of Colorectal Cancer

    SBC: PLx Opco Inc.            Topic: NCI

    ABSTRACT Colorectal cancerCRCis the third leading cause of cancer related deaths in the U SBased on numerous epidemiological studies and recent prospective clinical trialsthe use of daily aspirin is associated with a significant reduction in CRC incidencedeaths and metastatic spreadHoweverthe chronic use of this drug is limited due to the side effects of gastrointestinal bleeding ulceration in sus ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

    SBC: REMD BIOTHERAPEUTICS INC.            Topic: NIDDK

    DESCRIPTIONprovided by applicantFast TrackInsulin remains the primaryand often the onlytreatment for typediabetes mellitusT DHowever it is associated with chronic iatrogenic hyperinsulinemiasecondary hyperlipidemiahigher incidence and severity of cardiovascular complicationsand life threatening hypoglycemia eventsA higher mortalityvsdue to cardiovascular complications were reported in insulin trea ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Oral Small Molecule STAT Inhibitor to Treat Cachexia in Chronic Kidney Disease

    SBC: StemMed, Ltd.            Topic: 400

    DESCRIPTION provided by applicant Chronic kidney disease CKD is a major public health problem in the US with an estimated prevalence of million patients enter hemodialysis or peritoneal dialysis programs yearly A serious complication in of patients with CKD is cachexia or muscle wasting which decreases quality of life and increases morbidity and mortality Unfortunately ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Personalized dosing of dichloroacetate for the treatment of rare and common diseases

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Pyruvate dehydrogenase complexPDCdeficiencyPDCDis a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncatedTreatment of PDCD remains a seriousunmetchallengeThere has never been a controlled trial of any intervention for PDCDthusthere is no proven therapy for affected patientsDichloroacetateDCArepresents the first targeted therapy for ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Commercialization of a Novel Therapeutic for Alzheimer's Disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Lactoferrin Modulation of Granuloma Pathology

    SBC: Pharmareview Corporation            Topic: NIAID

    ABSTRACT Host immunity plays a major role in development of Tuberculosis diseaseTuberculosis infected individuals respond by formation of granulomaswhich contain bacilliHoweverorganisms within granulomas are protected from the full scope of immune mediated defensesWe hypothesize that modulation of destructive immune mediated pathologywhile preserving essential immune responseswill allow more effec ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. An eHealth solution for posttraumatic stress and pain screening integrated in pediatric injury care

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    ABSTRACT Pediatric injury is the leading cause of child mortality and acquired disability in the United Statesaffectingmillion children annuallyAmong school age children alonemore thanmillion are treated in Emergency Department or admitted to the hospital annually for injuryincurring billions in medical and work loss costs each yearAfter hospital dischargemany injured children experience pain that ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

    SBC: BIOVINC, LLC            Topic: NIDCR

    ABSTRACT Dental implants are a central part of modern dental practice with the overall market for replacement and reconstruction of teeth expected to reach over $billion in the next several yearsIt is estimated that overmillion people in the United States are missing all of the teeth in one or both of their jaws leading to lower quality of lifeMost of these implants will be successful for long ter ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government